
Dishman Carbogen Q2 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 1
Fundraise
No
Order
No
Capex
Yes
2 of 5 growth signals are positive.
Full analysisRevenue guidance
Category 3- Bavla site in India expects 25% to 30% growth in the next financial year, aiming to normalize operations and improve margins (Page 17).
- Overall company revenue growth estimated around 8% to 9% for the full fiscal year (Page 9).
- Carbogen Amcis targeting CHF 255 million revenue for FY '25 and is on track to achieve this (Page 8).
- CRAMS Carbogen Amcis business saw a commercial revenue growth of about 52% compared to last year Q2 (Page 6).
- Increase in inquiries and order books expected post-election, leading to new project capture in early 2025 (Pages 8, 9).
- French facility expected to reach break-even in the next financial year with revenue growth from €9.5 million in H1 to €18-19 million next year (Page 9).
- Long term goal to reach steady-state EBITDA margin of ~25-30% supported by improved operations in India, France, and reduction in raw material prices in Netherlands (Page 17).
See what Dishman Carbogen management said on margin guidance — free account, 30 seconds.
Fundraise plans
No- No plans to raise equity to repay debt as per Harshil Dalal.
- Interest rates (LIBOR/SOFR) are expected to decrease, reducing interest costs, making debt cheaper than equity.
- The company will continue managing hedging actively to handle foreign currency exposure.
- Focus is on generating free cash flow to reduce net debt over the next 2-2.5 years, targeting a net debt-to-EBITDA ratio below 2 by FY '27.
- No mention of new debt fundraising; emphasis is on maintaining and reducing current debt levels through cash flow rather than new borrowings.
See what Dishman Carbogen management said on order book — free account, 30 seconds.
Capex plans
Yes- Major capex related to growth has largely been completed; future capex will mainly be maintenance-focused.
- Total capex in the first half of the financial year was about INR125 crores; expected full-year capex around INR250 crores, including digital transformation activities.
- Discussions underway for a potential 2-digit million investment in a specific facility to debottleneck supply chain capacity, linked to a customer project ramp-up in the second half.
- Continued investment in digitalization and operational excellence to improve efficiency and profitability.
- No plans presently to raise equity for debt repayment; interest rates expected to decrease, reducing finance costs.
Track Dishman Carbogen — get its next earnings analysis in your feed
How does Dishman Carbogen rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Dishman Carbogen rank in Pharmaceuticals & Biotechnology?
Compare Dishman Carbogen against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Dishman Carbogen's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem